Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

NCT05152459 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Feasibility

Conditions

Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Tazemetostat
BIOLOGICAL: Ublituximab
DRUG: Umbralisib

Sponsor

City of Hope Medical Center

Collaborators

[object Object]